Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in interstitial lung disease-associated pulmonary hypertension
2007-003928-37Phase 2Active
- Sponsor
- Bayer
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of riociguat in pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), sponsored by Bayer. Primary endpoints: Safety and tolerability and Efficacy. Started Mar 2008; status: active.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension (PH)pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2007-003928-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003928-37.